Growth Hormone Therapy

Size: px
Start display at page:

Download "Growth Hormone Therapy"

Transcription

1 Growth Hormone Therapy Policy Number: Original Effective Date: MM /21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 04/24/2015 Section: Prescription Drugs Place(s) of Service: Home I. Description Growth hormone therapy is a long-term, injectable therapy primarily used in children and adolescents with documented growth hormone deficiencies. Human growth hormone (GH), also known as somatotropin, is synthesized in the somatotrophic cells of the pituitary gland. Since 1985, recombinant GH has been marketed as replacement therapy for children and adults with various diagnoses. II. Criteria/Guidelines Initial therapy with human growth hormone is covered (subject to Administrative Guidelines) for one of the following indications: A. Children with evidence of growth hormone deficiency (GHD) must meet the following criteria: 1. Biochemical Criteria: a. Documentation of abnormal responses to two growth hormone (GH) stimulation tests defined as less than 10 nanograms per milliliter (ng/ml) or as otherwise determined by the testing lab; or b. At least one GH stimulation test response less than15 ng/ml, and both IGF-l and IGF-BP3 levels below normal for age and gender; or c. One GH stimulation test response below 10 ng/ml with defined CNS pathology, history of cranial irradiation or genetic conditions associated with GHD; or d. Two or more documented pituitary hormone deficiencies other than GH; or e. Abnormally low GH level documented in association with neonatal hypoglycemia; and 2. Auxologic Criteria a. Height equal to or less than two standard deviations below the mean for age and gender; or b. Height equal to or less than one standard deviation below the mean and growth velocity less than one standard deviation below the mean for age and gender; and i. A minimum of one year of growth data is required with measurements at least six months apart and performed by an endocrinologist; or

2 Growth Hormone Therapy 2 ii. Patient must have four or more height determinations measured at least six months apart, by the patient s primary care physician, over a period of at least two years. Results must show a consistent growth pattern; and c. Radiologic documentation of open growth plates in patients over 12 years of age. B. Children with idiopathic short stature, familial short stature, or small for gestational age infants with failure of catch-up growth by the age of two must meet the following criteria: 1. Auxologic Criteria: a. Height less than or equal to 2.25 standard deviations below the mean for age and gender; and b. Growth velocity equal to or less than one standard deviation below the mean for age and gender measured in accordance with II.A.2.b; and c. Radiologic documentation of open growth plates in patients over 12 years of age. C. Turner s syndrome: Patients must meet the following criteria: 1. Open growth plates in patients over 12 years of age; and 2. Height below the tenth percentile for age. D. Noonan s syndrome: Patients must meet the following criteria: 1. Open growth plates in patients over 12 years of age; and 2. Height below the tenth percentile for age and gender. E. Prader-Willi syndrome: Patients must meet the following criteria: 1. Open growth plates in patients over 12 years of age; and 2. Height below the tenth percentile for age and gender. F. Children with chronic renal insufficiency: Patients must meet the following criteria: 1. Creatinine clearance less than or equal to 75 ml/min per 1.73 m 2 or serum creatinine greater than 3.0 mg/dl, or dialysis dependent; and 2. Radiographic documentation of open growth plates in patients over 12 years of age; and G. Acquired Immune Deficiency Syndrome (AIDS) wasting: Patients must meet the following criteria: 1. Greater than 10 percent of baseline weight loss that cannot be explained by a concurrent illness other than HIV infection; and 2. Simultaneous treatment with antiviral agents. H. Burn patients: Patients must meet the following criteria: 1. Extensive 3rd-degree burns; or 2. Burns greater than or equal to 40 percent total body surface area. I. Short bowel syndrome: Patients must meet the following criteria: 1. Receiving specialized nutritional support; and 2. Optimal management of short bowel syndrome.

3 Growth Hormone Therapy 3 J. Adults with evidence of GH deficiency 1. Irreversible hypothalamic/pituitary structural lesions or ablation: no further testing needed. 2. Defect in GH synthesis: no further testing needed. 3. GH deficiency in childhood, circumstances other than J.1 or J.2. Only about 25% of children with GH deficiency will be found to have GH deficiency as adults. Therefore, once adult height has been achieved, patients should be retested for GH deficiency after at least a one month break in GH therapy to determine if continuing replacement is necessary in accordance with one of the following criteria: a. Three or more pituitary hormone deficiencies and IGF-1 level below laboratory s range of normal: no further testing necessary; b. Peak GH level in response to insulin tolerance test less than or equal to 5.0 ng/ml and IGF-1 level below laboratory's range of normal; c. Peak GH level in response to glucagon stimulation test less than or equal to 3.0 ng/ml and IGF-1 level below laboratory's range of normal; d. Peak GH level in response to arginine stimulation test less than or equal to 0.4 ng/ml and IGF-1 level below laboratory's range of normal. Note: Levadopa and clonidine stimulation tests are not acceptable for documenting persistence of GH deficiency into adulthood. Continuation of therapy is covered (subject to Limitations and Administrative Guidelines) when the continuation of therapy criteria listed in the chart below (in Administrative Guidelines) are met. III. Administrative Guidelines A. Precertification is required. To precertify, please complete HMSA's Precertification Request and mail or fax the form as indicated. B. Children approved for GHT under previous HMSA policies will be approved for continuation of therapy in accordance with current continuation criteria. C. Children receiving GHT without previous HMSA authorization will be considered for continuation of therapy in accordance with current initiation criteria (per clinical data prior to initiation of therapy) and current continuation criteria (per current clinical data). D. Children previously treated with GHT but who have had treatment subsequently discontinued will be considered for re-initiation of therapy in accordance with current initial treatment criteria (per current clinical data) and continuation criteria except growth velocity (per current clinical data).

4 Growth Hormone Therapy 4 Table 1 Indication Pediatric short stature Turner s syndrome Noonan s syndrome Prader-Willi syndrome Chronic Renal Insufficiency Adult GHD Burn patients Short bowel syndrome AIDS wasting Table 2 Indication Growth hormone deficiency Pediatric short stature Turner s syndrome Noonan s syndrome Prader-Willi syndrome Chronic Renal Insufficiency Adult GHD Short bowel syndrome Burn patients AIDS wasting Initial Authorization Period Up to 12 months Up to 12 months Four weeks Up to 12 months Continuation of Therapy Approved in 12 month increments with current documentation of: Growth velocity greater than or equal to two centimeters per year; and Open growth plates in children over 12 years of age; and Height less than fifth percentile of normal adult height for gender (150 centimeters for girls, 165 centimeters for boys). Can be approved in 12 month increments No further authorization shall be given Codes J2941 and NDC number Description Injection somatropin, 1 mg (e.g. Nutropin/Nutropin AQ) IV. Important Reminder The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

5 Growth Hormone Therapy 5 Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control. This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii s Patients Bill of Rights and Responsibilities Act (Hawaii Revised Statutes 432E-1.4), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA s determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation. V. References 1. AACE Guidelines for clinical practice for growth hormone use in adults and children, 2003 update. Endocrine Practice Vol 9 No. 1 Jan/Feb American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients 2009 update. 3. Centers for Disease Control and Prevention. Growth Charts. Accessed 11/25/ Cohen P, Rogol AD, Deal CL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab. Nov 2008; 93(11): Consensus Guidelines for the Diagnosis and Treatment of Adults with Growth Hormone Deficiency: Summary Statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone 6. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients update. Endocrinology Practice 2009 Sep-Oct; 15 Suppl 2: Deal CL, Tony M, Hoybye C, et al. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. Jun 2013;98(6):E Deficiency, Journal of Clinical Endocrinology & Metabolism, :2, Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML, American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients update. Endocrinology Practice Sep-Oct; 15 Suppl 2: Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab Jun; 96(6): Human Growth Hormone. Blue Cross Blue Shield Association Medical Policy Reference Manual. Policy , October 2014.

6 Growth Hormone Therapy Genentech product information, Nutropin/Nutropin AQ, June GH Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone deficiency in childhood and adolescence: summary statement of the GH Research Society. Journal of Clinical Endocrinology & Metabolism 2000; 85(11): National Institute for Health and Clinical Excellence (NICE). Human growth hormone (somatropin) for growth failure in children: NICE guidance 188. May Rosenfeld RG et al. Diagnostic controversy: The diagnosis of childhood growth hormone deficiency revisited. Journal of Clinical Endocrinology & Metabolism 1995; 80: Tanner JM et al. Clinical longitudinal standards for height and height velocity for North American children. Journal of Pediatrics 1985; 107(3): Wilson TA, Rose SR, Cohen P, et.al., Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Journal of Pediatrics. 2003; Oct. 143(4): Wood AJ. Treatments for wasting in patients with the acquired immunodeficiency syndrome. New England. Journal of Medicine 1999; 340(22): VI. Appendix The values corresponding to specific z-scores are contained in this Excel data file. This file contains the z-scores values for gender (1=male; 2=female). For example, 1.5 months represents months. The only exception is birth, which represents the point at birth. Centers for Disease Control and Prevention Growth Chart Z- Score Data Files

Growth Hormone Therapy

Growth Hormone Therapy Growth Hormone Therapy Policy Number: Original Effective Date: MM.04.011 05/21/1999 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/28/2011 Section: Prescription Drugs Place(s) of Service:

More information

GROWTH HORMONE THERAPY

GROWTH HORMONE THERAPY GROWTH HORMONE THERAPY Line(s) of Business: HMO; PPO; QUEST Integration Original Effective Date: 05/21/1999 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below including FDA-approved

More information

FDA Approved Indications

FDA Approved Indications Preferred Agents: Humatrope (somatropin) Nutropin (somatropin) Medication Nutropin AQ (somatropin) Nutropin AQ NuSpin (somatropin) Non-Preferred Agents: Genotropin (somatropin) Omnitrope (somatropin) Norditropin

More information

Prior Authorization Form

Prior Authorization Form Prior Authorization Form Growth Hormone This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS/Caremark at

More information

Growth Hormone Deficiency

Growth Hormone Deficiency Growth Hormone Deficiency What is growth hormone deficiency? 1,2 Growth hormone deficiency is when your body doesn t make enough growth hormone. Growth hormone is one of many hormones made by the pituitary

More information

Obtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature In 2003, the Food and Drug Administration (FDA) approved

Obtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature In 2003, the Food and Drug Administration (FDA) approved Obtaining insurance coverage for human growth hormone treatment for Idiopathic Short Stature In 2003, the Food and Drug Administration (FDA) approved the use of growth hormone (GH) for the long-term treatment

More information

Policy/Criteria: Human Growth Hormone may be considered medically necessary if the following conditions are met:

Policy/Criteria: Human Growth Hormone may be considered medically necessary if the following conditions are met: This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutics

More information

Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER

Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER Endocrine issues in FA SUSAN R. ROSE CINCINNATI CHILDREN S HOSPITAL MEDICAL CENTER 80% of children and adults with FA have an endocrine abnormality Endocrine cells make a hormone (message) Carried in bloodstream

More information

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder

Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Applied Behavior Analysis Therapy for Treatment of Autism Spectrum Disorder Policy Number: Original Effective Date: MM.12.022 01/01/2016 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration

More information

Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices

Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices Patient Satisfaction and Therapeutic Adherence Considerations of rhgh Dosing Devices Robert Lipsy, PharmD Clinical Assistant Professor Department of Pharmacy Practice and Sciences University of Arizona

More information

External Insulin Pumps Corporate Medical Policy

External Insulin Pumps Corporate Medical Policy External Insulin Pumps Corporate Medical Policy File name: External Insulin Pumps File code: UM.DME.02 Origination: 4/2006 Last Review: 02/2014 (ICD-10 remediation only) Next Review: 10/2014 Effective

More information

Recombinant human growth hormone therapy may be considered medically necessary for the following patients:

Recombinant human growth hormone therapy may be considered medically necessary for the following patients: ϯ ϯ ϯ A Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association PRIOR AUTHORIZATION: GROWTH HORMONE Coverage Recombinant

More information

Growth Hormone Deficiency A Guide for Parents and Patients

Growth Hormone Deficiency A Guide for Parents and Patients Growth Hormone Deficiency A Guide for Parents and Patients SERIES 1 SERIES 2 SERIES 3 SERIES 4 SERIES 5 SERIES 6 SERIES 7 SERIES 8 SERIES 9 SERIES 10 SERIES 11 SERIES 12 SERIES 13 SERIES 14 SERIES 15 SERIES

More information

USEFULNESS OF BONE AGE IN PAEDIATRIC ENDOCRINOLOGY. Rina Balducci Center of Pediatric Endocrinology, Department of Public Health and Cell Biology

USEFULNESS OF BONE AGE IN PAEDIATRIC ENDOCRINOLOGY. Rina Balducci Center of Pediatric Endocrinology, Department of Public Health and Cell Biology USEFULNESS OF BONE AGE IN PAEDIATRIC ENDOCRINOLOGY Gian Luigi Spadoni and Stefano Cianfarani Rina Balducci Center of Pediatric Endocrinology, Department of Public Health and Cell Biology Tor Vergata University,

More information

Hawaii Benchmarks Benefits under the Affordable Care Act (ACA)

Hawaii Benchmarks Benefits under the Affordable Care Act (ACA) Hawaii Benchmarks Benefits under the Affordable Care Act (ACA) 10/2012 Coverage for Newborn and Foster Children Coverage Outside the Provider Network Adult Routine Physical Exams Well-Baby and Well-Child

More information

Short Synacthen Test for the Investigation of Adrenal Insufficiency

Short Synacthen Test for the Investigation of Adrenal Insufficiency Pathology at the Royal Derby Hospital Short Synacthen Test Standard Clinical Guidelines Chemical Pathology Department Valid Until 31 st March 2015 Document Code: CHISCG1 Short Synacthen Test for the Investigation

More information

testosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015

testosterone_pellet_implantation_for_androgen_deficiency_in_men 10/2015 N/A 11/2016 10/2015 This policy is not effective until December 30, 2015 Corporate Medical Policy Testosterone Pellet Implantation for Androgen Deficiency in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: testosterone_pellet_implantation_for_androgen_deficiency_in_men

More information

Hypothyroidism. Written by Donald Yung Edited by Dianna Louie. Basic Embryology and Anatomy

Hypothyroidism. Written by Donald Yung Edited by Dianna Louie. Basic Embryology and Anatomy Hypothyroidism Written by Donald Yung Basic Embryology and Anatomy The thyroid gland consists of two lobes connected by an isthmus and is located anterior to the trachea at the base of the neck. During

More information

Modifier Usage Guide What Your Practice Needs to Know

Modifier Usage Guide What Your Practice Needs to Know BlueCross BlueShield of Mississippi Modifier Usage Guide What Your Practice Needs to Know Modifier 22 Usage Modifier 22 - Procedural Service The purpose of this modifier is to report services (surgical

More information

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C:

The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C: The sensitive marker for glomerular filtration rate (GFR) Estimation of GFR from Serum Cystatin C: The good correlation allows close estimation of GFR Cystatin C GFR GFR in serum estimated* measured* n

More information

Insulin Infusion Pumps

Insulin Infusion Pumps Medical Coverage Policy Insulin Infusion Pumps EFFECTIVE DATE: 09/01/2004 POLICY LAST UPDATED: 08/06/2013 OVERVIEW The policy addresses insulin infusion pumps that are worn externally and those that are

More information

POLICY A. INDICATIONS

POLICY A. INDICATIONS Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: 10/01/2015 POLICY A. INDICATIONS The indications below

More information

Healthcare services requiring prior authorisation

Healthcare services requiring prior authorisation Annex 2 Healthcare requiring prior authorisation This list does not include organ transplants and does also not apply to long-term care and the primary purpose of which is to support people in need of

More information

Failure to Thrive: Rethinking Our Treatment Goals Darren Fiore, MD 2013 Advances & Controversies in Clinical Pediatrics. Tips and Reference Sheet

Failure to Thrive: Rethinking Our Treatment Goals Darren Fiore, MD 2013 Advances & Controversies in Clinical Pediatrics. Tips and Reference Sheet Failure to Thrive: Rethinking Our Treatment Goals Darren Fiore, MD 2013 Advances & Controversies in Clinical Pediatrics Tips and Reference Sheet Various Definitions of FTT: Weight < 5th percentile for

More information

Nursing - Graduate (NGRD)

Nursing - Graduate (NGRD) Loma Linda University 2015-2016 1 Nursing - Graduate (NGRD) Courses NGRD 500. Primary Care Adult-Gerontology Nurse Practioner: Fragile elders. 2 Continues development of the A-GNP role of health promotion,

More information

Endocrine Causes of Chronic Fatigue Syndrome (CFS)/Chronic Fatigue Immune. Deficiency Syndrome (CFIDS):

Endocrine Causes of Chronic Fatigue Syndrome (CFS)/Chronic Fatigue Immune. Deficiency Syndrome (CFIDS): 1 Endocrine Causes of Chronic Fatigue Syndrome (CFS)/Chronic Fatigue Immune Deficiency Syndrome (CFIDS): A Brief Guide for Patients and Primary Care Physicians Theodore C. Friedman and Camille Kimball

More information

Application for Medicare Supplement

Application for Medicare Supplement Application for Medicare Supplement This application is subject to the approval of Blue Cross and Blue Shield of Nebraska. P.O. Box 2417 Omaha, NE 68103-2417 1 Tell us about yourself. Name (First, Middle,

More information

Application for Medicare Supplement Insurance Plan

Application for Medicare Supplement Insurance Plan Application for Medicare Supplement Insurance Plan Instructions Complete this application in ink and sign on the appropriate line in PART THREE. To be considered for coverage, you must be age 65 or over,

More information

Figure showing the relationship of the pituitary and hypothalamus and the sex hormone axis

Figure showing the relationship of the pituitary and hypothalamus and the sex hormone axis GONADOTROPHIN RELEASING HORMONES ANALOGUES USAGE IN THE MANAGEMENT OF PRECOCIOUS PUBERTY. Professor Peter Hindmarsh University College London Hospitals Background Puberty arises as a result of an increase

More information

Beyond the Basics of Endocrine Stimulation Testing Las Vegas, NV. Conflict of Interest Disclosure 4/17/2013

Beyond the Basics of Endocrine Stimulation Testing Las Vegas, NV. Conflict of Interest Disclosure 4/17/2013 Beyond the Basics of Endocrine Stimulation Testing Las Vegas, NV Earline Edwards MSN, APRN NP, CPNP, CDE University of NE Medical Center Children s Hospital Omaha, NE Conflict of Interest Disclosure Advisory

More information

Physical Therapy MM.09.005 07/15/2003

Physical Therapy MM.09.005 07/15/2003 Physical Therapy Policy Number: Original Effective Date: MM.09.005 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; EUTF; HSTA; QUEST; Federal Plan 87 09/28/2012 Line(s) of Business Excluded:

More information

Hypothyroidism clinical features and treatment. 1. The causes of hypothyroidism

Hypothyroidism clinical features and treatment. 1. The causes of hypothyroidism Hypothyroidism clinical features and treatment 1. The causes of hypothyroidism The thyroid is a gland in the neck which makes two thyroid hormones, thyroxine (T4) and tri-iodothyronine (T3). Thyroxine

More information

At the completion of training, the resident will have acquired the following competencies and will function effectively as a:

At the completion of training, the resident will have acquired the following competencies and will function effectively as a: Objectives of Training in the Subspecialty of Endocrinology and Metabolism This document applies to those who begin training on or after July 1 st, 2013. DEFINITION 2013 VERSION 2.0 Endocrinology and Metabolism

More information

Occupational Therapy

Occupational Therapy Occupational Therapy Policy Number: Original Effective Date: MM.09.003 07/15/2003 Line(s) of Business: Current Effective Date: HMO; PPO; EUTF; HSTA; QUEST; Federal Plan 87 02/01/2012 Line(s) of Business

More information

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation

More information

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps)

Criteria: CWQI HCS-123 (This criteria is consistent with CMS guidelines for External Infusion Insulin Pumps) Moda Health Plan, Inc. Medical Necessity Criteria Subject: Origination Date: 05/15 Revision Date(s): 05/2015 Developed By: Medical Criteria Committee 06/24/2015 External Infusion Insulin Pumps Page 1 of

More information

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health

Overview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-290-1278 Fax: 425-918-5278

P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-290-1278 Fax: 425-918-5278 Oregon Medicare Supplement Enrollment Application for Plans A, F, High Deductible F and N P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-290-1278 Fax: 425-918-5278 You are eligible to apply for a

More information

A Parent s Guide to Understanding Congenital Hypothyroidism. Children s of Alabama Department of Pediatric Endocrinology

A Parent s Guide to Understanding Congenital Hypothyroidism. Children s of Alabama Department of Pediatric Endocrinology A Parent s Guide to Understanding Congenital Hypothyroidism Children s of Alabama Department of Pediatric Endocrinology How did you get here? Every baby born in the state of Alabama is required by law

More information

University of Michigan Group: 007005187-0000, 0001 Comprehensive Major Medical (CMM) Benefits-at-a-Glance

University of Michigan Group: 007005187-0000, 0001 Comprehensive Major Medical (CMM) Benefits-at-a-Glance University of Michigan Group: 007005187-0000, 0001 Comprehensive Major Medical (CMM) Benefits-at-a-Glance This is intended as an easy-to-read summary and provides only a general overview of your benefits.

More information

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes DIABETES MELLITUS DEFINITION It is a common, chronic, metabolic syndrome characterized by hyperglycemia as a cardinal biochemical feature. Resulting from absolute lack of insulin. Abnormal metabolism of

More information

Benefit Summary - A, G, C, E, Y, J and M

Benefit Summary - A, G, C, E, Y, J and M Benefit Summary - A, G, C, E, Y, J and M Benefit Year: Calendar Year Payment for Services Deductible Individual $600 $1,200 Family (Embedded*) $1,200 $2,400 Coinsurance (the percentage amount the Covered

More information

Ordering and interpreting thyroid tests in children. Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC

Ordering and interpreting thyroid tests in children. Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC Ordering and interpreting thyroid tests in children Paul Kaplowitz, MD, PhD Children s National Medical Center, Washington, DC Objectives To review indications for thyroid testing To discuss which tests

More information

Continuity Clinic Educational Didactic. December 8 th December 12 th

Continuity Clinic Educational Didactic. December 8 th December 12 th Continuity Clinic Educational Didactic December 8 th December 12 th MKSAP Question 1 A 60-year-old man is evaluated for a 1-year history of generalized fatigue and lack of energy. He has had erectile dysfunction

More information

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,

More information

SUMMARY TABLE OF MEASURE CHANGES

SUMMARY TABLE OF MEASURE CHANGES Summary Table of Measure 1 SUMMARY TABLE OF MEASURE CHANGES Guidelines for Physician Measurement Effectiveness of Preventive Care Guidelines for Physician Effectiveness of Care Adult BMI Assessment Weight

More information

Application for Senior Medicare Supplement Plans BLUE CROSS AND BLUE SHIELD OF MONTANA P.O. BOX 4309 HELENA, MT 59604

Application for Senior Medicare Supplement Plans BLUE CROSS AND BLUE SHIELD OF MONTANA P.O. BOX 4309 HELENA, MT 59604 Application for Senior Medicare Supplement Plans BLUE CROSS AND BLUE SHIELD OF MONTANA P.O. BOX 4309 HELENA, MT 59604 SENIORAPP062010 FLD New Enrollment Change Benefit Plan (e.g., Plan F to Plan C) Transfer

More information

Kyphoplasty and Vertebroplasty

Kyphoplasty and Vertebroplasty Kyphoplasty and Vertebroplasty Policy Number: Original Effective Date: MM.06.007 01/11/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 10/26/2012 Section: Surgery Place(s) of Service:

More information

Endocrine Responses to Resistance Exercise

Endocrine Responses to Resistance Exercise chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to

More information

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES

HAWAII BOARD OF MEDICAL EXAMINERS PAIN MANAGEMENT GUIDELINES Pursuant to section 453-1.5, Hawaii Revised Statutes, the Board of Medical Examiners ("Board") has established guidelines for physicians with respect to the care and treatment of patients with severe acute

More information

HEALTH DEPARTMENT BILLING GUIDELINES

HEALTH DEPARTMENT BILLING GUIDELINES HEALTH DEPARTMENT BILLING GUIDELINES Acknowledgement: Current Procedural Terminology (CPT ) is copyright 2015 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative

More information

Traditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes

Traditional View of Diabetes. Are children with type 1 diabetes obese: What can we do? 8/9/2012. Change in Traditional View of Diabetes Are children with type 1 diabetes obese: What can we do? Traditional View of Diabetes Type 1 Diabetes ( T1DM) Onset Juvenile Lean Type 2 Diabetes ( T2DM) Onset Adult Obese QI Project Indrajit Majumdar

More information

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and

UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and UNDERSTANDING MULTIPLE MYELOMA AND LABORATORY VALUES Benjamin Parsons, DO bmparson@gundersenhealth.org Gundersen Health System Center for Cancer and Blood Disorders La Crosse, WI UNDERSTANDING MULTIPLE

More information

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage.

Department Of Biochemistry. Subject: Diabetes Mellitus. Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Department Of Biochemistry Subject: Diabetes Mellitus Supervisor: Dr.Hazim Allawi & Dr.Omar Akram Prepared by : Shahad Ismael. 2 nd stage. Diabetes mellitus : Type 1 & Type 2 What is diabestes mellitus?

More information

KIDNEY/PANCREAS REFERRAL PACKET Please attach the following information with each application.

KIDNEY/PANCREAS REFERRAL PACKET Please attach the following information with each application. KIDNEY/PANCREAS REFERRAL PACKET Please attach the following information with each application. 1. Patient s history and physical (less than one year old). 2. Recent labs, current medication list and radiology

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Medical Clinical Assistant

Medical Clinical Assistant Medical Clinical Assistant Pennsylvania CIP 51.0801 This document describes the correlation between curriculum, supplied by Applied Educational Systems, and the Medical Clinical Assistant standard, published

More information

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS

Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS Testosterone; What s all the hype? KRISTEN WYRICK, LTCOL,USAFR, MC USUHS, FAMILY MEDICINE JOINT BASE LANGLEY-EUSTIS The faces of Low Testosterone What your patients are seeing Pharmacy Industry Testosterone

More information

ELECTROMYOGRAPHY (EMG), NEEDLE, NERVE CONDUCTION STUDIES (NCS) AND QUANTITATIVE SENSORY TESTING (QST)

ELECTROMYOGRAPHY (EMG), NEEDLE, NERVE CONDUCTION STUDIES (NCS) AND QUANTITATIVE SENSORY TESTING (QST) AND QUANTITATIVE SENSORY TESTING (QST) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical

More information

Insulin like Growth Factor 1 as an Indicator of Growth Hormone Deficiency

Insulin like Growth Factor 1 as an Indicator of Growth Hormone Deficiency Insulin like Growth Factor 1 as an Indicator of Growth Hormone Deficiency Hussein Alawneh MD *, Omar Khaledi MD *, Jamal Maita MD *, Neveen Fugaha RN **, Raeda Otoom RN **, Mohammad Shatnawi MD * ABSTRACT

More information

HI-IQ details available online

HI-IQ details available online HMSA s For Participating Medical Practitioners MAY 2007 INDEX draft medical policies 2 bluecard cdhp 2 locum tenens 3 immunization mac changes 3 referring physician name 4 annual review of policies 4 alglucosidase

More information

Benefit Coverage Chart & Rates Effective July 1, 2014 June 30, 2015

Benefit Coverage Chart & Rates Effective July 1, 2014 June 30, 2015 Benefit Coverage Chart & Rates Effective PPO Medical Coverage by Category The following coverages are included with the PPO plan: o Prescription o Vision Additional Benefits o Dental o Dental & Orthodontia

More information

REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF

REFERENCE ACTION ANALYST STAFF DIRECTOR or BUDGET/POLICY CHIEF HOUSE OF REPRESENTATIVES STAFF ANALYSIS BILL #: CS/HB 1041 Controlled Substances SPONSOR(S): Criminal Justice Subcommittee; Berman TIED BILLS: IDEN./SIM. BILLS: CS/SB 1448 REFERENCE ACTION ANALYST STAFF

More information

Diabetes mellitus. Lecture Outline

Diabetes mellitus. Lecture Outline Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized

More information

REGISTERED NURSE PRACTITIONER (RNP) PRACTICING IN AN ACUTE CARE SETTING October 2009 Adopted by the Board 11/19/09 Background

REGISTERED NURSE PRACTITIONER (RNP) PRACTICING IN AN ACUTE CARE SETTING October 2009 Adopted by the Board 11/19/09 Background Janice Brewer Governor Joey Ridenour Executive Director Arizona State Board of Nursing 4747 N. 7 th Street Phoenix, AZ 85014-3653 Phone (602) 771-7888 Fax (602) 771-7800 E-Mail: prandolph@azbn.gov Home

More information

NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM

NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal Code: Country: Phone Number:

More information

APPLICATION FOR THE RN to BSN PROGRAM NAME: ADDRESS:

APPLICATION FOR THE RN to BSN PROGRAM NAME: ADDRESS: APPLICATION FOR THE RN to BSN PROGRAM PLEASE PRINT CLEARLY NAME: ADDRESS: Please check Campus you wish to attend: Rutgers Camden: Atlantic Cape Community College: Camden County College at Blackwood: Home

More information

Schedule of Benefits Summary. Health Plan. Out-of-network Provider

Schedule of Benefits Summary. Health Plan. Out-of-network Provider Schedule of Benefits Summary University Name: University of Nebraska - Student Plan Health Plan : 2014/2015 Academic Year (see attached) Payment for Services Covered Services are reimbursed based on the

More information

P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-752-6663 Fax: 425-918-5278

P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-752-6663 Fax: 425-918-5278 Washington Medicare Supplement Enrollment Application for Plans A, F, High Deductible F and N P.O. Box 91120, MS 295 Seattle, WA 98111-9220 1-800-752-6663 Fax: 425-918-5278 ou are eligible to apply for

More information

Meaningful Use Objectives

Meaningful Use Objectives Meaningful Use Objectives The purpose of the electronic health records (EHR) incentive program is not so much the adoption of health information technology (HIT), but rather how HIT can further the goals

More information

Medical Terminology APS-100-TE. TECEP Test Description

Medical Terminology APS-100-TE. TECEP Test Description Medical Terminology APS-100-TE This TECEP tests the material usually taught in a course on the everyday medical terminology used by healthcare and medical professionals. It focuses on the word parts, word

More information

Preventing Pediatric Diabetes: Are Racial Disparities A Factor? A Children s Health Fund Issue Brief February 2004

Preventing Pediatric Diabetes: Are Racial Disparities A Factor? A Children s Health Fund Issue Brief February 2004 Preventing Pediatric Diabetes: Are Racial Disparities A Factor? A Children s Health Fund Issue Brief February 2004 The Children s Health Fund The Children s Health Fund (CHF), working with hospitals and

More information

2015 Orange County HICAP Medicare Advantage Special Needs Plans Comparison Chart

2015 Orange County HICAP Medicare Advantage Special Needs Plans Comparison Chart Brand New Day Brand New Day Brand New Day Brand New Day Bridges Drug Savings Bridges Extra Care Harmony Healthy Heart Drug Savings dementia. dementia. chronic and disabling mental health conditions. chronic

More information

CYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE

CYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE CYSTIC FIBROSIS CLINICS AS A MODEL OF INTERPROFESSIONAL CARE 1. Cystic fibrosis introduction 2. CF Foundation centers 3. Care disciplines: physician specialists (pulmonary, GI, endocrine, genetics, palliative

More information

Hypogonadism and Testosterone Replacement in Men with HIV

Hypogonadism and Testosterone Replacement in Men with HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hypogonadism and Testosterone Replacement in Men with HIV Stephanie T. Page, MD, PhD Robert B. McMillen Professor in Lipid Research, Associate Professor of

More information

Last name First name Middle initial Social Security number (required)

Last name First name Middle initial Social Security number (required) Alaska Medicare Supplement Enrollment Application for Plans A, F, High Deductible F and N 2550 Denali St., Suite 1404 Anchorage, AK 99503 1-888-669-2583 Fax: 907-258-1619 ou are eligible to apply for a

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Human Growth Hormone Page 1 of 33 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Human Growth Hormone Pre-Determination of Services IS REQUIRED by the Member s

More information

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University

Tuberculosis And Diabetes. Dr. hanan abuelrus Prof.of internal medicine Assiut University Tuberculosis And Diabetes Dr. hanan abuelrus Prof.of internal medicine Assiut University TUBERCULOSIS FACTS More than 9 million people fall sick with tuberculosis (TB) every year. Over 1.5 million die

More information

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY:

MEDICAL COVERAGE POLICY. SERVICE: Insulin Pump and Continuous Glucose Monitoring. PRIOR AUTHORIZATION: Required. POLICY: Important note Even though this policy may indicate that a particular service or supply may be considered covered, this conclusion is not based upon the terms of your particular benefit plan. Each benefit

More information

The Influence of Infant Health on Adult Chronic Disease

The Influence of Infant Health on Adult Chronic Disease The Influence of Infant Health on Adult Chronic Disease Womb to Tomb Dr Clare MacVicar Introduction Many diseases in adulthood are related to growth patterns during early life Maternal nutrition important

More information

TABLE OF CONTENTS. Home Infusion Therapy Guidelines... 2

TABLE OF CONTENTS. Home Infusion Therapy Guidelines... 2 TABLE OF CONTENTS Home Infusion Therapy Guidelines... 2 Services normally considered eligible for benefits... 2 Description... 2 Pre-certification Requirements... 3 Billing Guidelines... 3 Home Infusion

More information

BULLETIN. Slovak Republic Ministry of Health

BULLETIN. Slovak Republic Ministry of Health BULLETIN Slovak Republic Ministry of Health Part 51-53 November 13, 2009 No. 57 CONTENTS: 52. Slovak Republic Ministry of Health Guidelines for the Diagnosis of Glucocorticoidinduced Osteoporosis 52. Slovak

More information

Practice Guidelines. Professional Practice Medical Record Documentation Guidelines

Practice Guidelines. Professional Practice Medical Record Documentation Guidelines Practice Guidelines 2010 Professional Practice Medical Record Documentation Guidelines Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage

More information

Vetsulin. CurveKit. Unparalleled support for managing canine and feline diabetes only from Merck Animal Health

Vetsulin. CurveKit. Unparalleled support for managing canine and feline diabetes only from Merck Animal Health Vetsulin CurveKit Glucose curve workpad How-to instructions Interpretation guidelines Unparalleled support for managing canine and feline diabetes only from Merck Animal Health How to chart your patients

More information

Administering DTaP during the Shortage

Administering DTaP during the Shortage PROVIDER SERVICES Policies/ Procedures/ Claims HMO 215/567-3590 800/227-3119* PPO 800/332-2566 PHARMACY SERVICES Prescription Drug Authorization 888/671-5280 Toll-Free Fax 888/671-5285 Blood Glucose Meter

More information

BlueSecure HMO Plan Benefit Summary

BlueSecure HMO Plan Benefit Summary BlueSecure HMO Plan Benefit Summary NETWORK LIMITATIONS NETWORK PROVIDERS ALLOWED AMOUNT Except for emergencies, all covered services must be rendered by a network provider. Outside Arizona, this plan

More information

NURSE PRACTITIONER STANDARDS FOR PRACTICE

NURSE PRACTITIONER STANDARDS FOR PRACTICE NURSE PRACTITIONER STANDARDS FOR PRACTICE February 2012 Acknowledgement The Association of Registered Nurses of Prince Edward Island gratefully acknowledges permission granted by the Nurses Association

More information

Member s responsibility (deductibles, copays, coinsurance and dollar maximums)

Member s responsibility (deductibles, copays, coinsurance and dollar maximums) MICHIGAN CATHOLIC CONFERENCE January 2015 Benefit Summary This is intended as an easy-to-read summary and provides only a general overview of your benefits. It is not a contract. Additional limitations

More information

Diagnosis, classification and prevention of diabetes

Diagnosis, classification and prevention of diabetes Diagnosis, classification and prevention of diabetes Section 1 1 of 4 Curriculum Module II 1 Diagnosis, classification and presentation of diabetes Slide 2 of 48 Polyurea Definition of diabetes Slide 3

More information

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections. National Diabetes Statistics What is diabetes? Diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.

More information

N Basic, including 100% Part B coinsurance. Basic including 100% Part B coinsurance* Basic including 100% Part B coinsurance

N Basic, including 100% Part B coinsurance. Basic including 100% Part B coinsurance* Basic including 100% Part B coinsurance HEARTLAND NATIONAL LIFE INSURANCE COMPANY Outline of Medicare Supplement Coverage Benefit Plans A, D, F, G, M and N Benefit Chart of Medicare Supplement Plans Sold for Effective Dates on or After Jun 1,

More information

Graves disease in childhood Antithyroid drug therapy

Graves disease in childhood Antithyroid drug therapy 83rd Annual Meeting of the ATA October 620, 203 Duration of antithyroid drugs treatment Disclosure Nothing to disclose Pr Juliane Léger Paediatric Endocrinology Department Paris Diderot University Hôpital

More information

Committee Approval Date: October 14, 2014 Next Review Date: March 2015

Committee Approval Date: October 14, 2014 Next Review Date: March 2015 Medication Policy Manual Topic: Testosterone replacement therapy products: - Androderm, - Axiron, - Fortesta, - Striant, - Testim Gel, - Natesto, - Vogelxo Policy No: dru297 Date of Origin: March 15, 2013

More information

Diabetes Medications: Insulin Therapy

Diabetes Medications: Insulin Therapy Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta

More information

SHIIP Combo Form. 1-855-408-1212 www.ncshiip.com. North Carolina Department of Insurance Wayne Goodwin, Commissioner

SHIIP Combo Form. 1-855-408-1212 www.ncshiip.com. North Carolina Department of Insurance Wayne Goodwin, Commissioner SHIIP Combo Form Seniors Health Insurance Information Program North Carolina Department of Insurance Wayne Goodwin, Commissioner 1-855-408-1212 www.ncshiip.com What is SHIIP? Seniors Health Insurance Information

More information

Conroe Physician Associates. Patient Consent Form. I fully understand that this is given in advance of any specific diagnosis or treatment.

Conroe Physician Associates. Patient Consent Form. I fully understand that this is given in advance of any specific diagnosis or treatment. Conroe Physician Associates Patient Consent Form Please Read and Sign I, undersigned, hereby consent to the following: Administration and performance of all treatments Administration of any needed anesthetics

More information

Understanding Growth: Normal vs. Abnormal Patterns Facilitator s Guide

Understanding Growth: Normal vs. Abnormal Patterns Facilitator s Guide Understanding Growth: Normal vs. Abnormal Patterns Facilitator s Guide Case Author: Laurie E. Cohen, MD Harvard Medical School Children s Hospital, Boston Case Advisors: S. Jean Emans, MD John R. Knight,

More information

The State Health Benefits Program Plan

The State Health Benefits Program Plan State of New Jersey Department of the Treasury Division of Pensions and Benefits STATE HEALTH BENEFITS PROGRAM PLAN COMPARISON SUMMARY FOR STATE EMPLOYEES EFFECTIVE APRIL 1, 2008 (March 29, 2008 for State

More information